Yeah, it rained last week in San Francisco. But the rain did not stop untold thousands of us from gathering at the many hotels, watering holes, and coffee shops around…
I believe it is fair to say that 2016 was a bit unusual. Thinking about the terminology many of us learned last year leads us to that conclusion: snowflake,…
The recent elections in the United States is bringing many long-standing policies into question. And, the continued legalization of marijuana is one of them. At Lacerta Bio, we have consistently…
Few of us will soon forget waking up in Cologne to the news that we will soon have a "President Trump" in the Oval Office in a few months. So,…
BIO Europe was, yet again, an excellent conference for Lacerta Bio. Having the US election on television screens in the Exhibition Hall made for some surreal moments and discussions. Not a…
Can we ESKAPE the problem which may kill thousands of human beings over the next decades? First, what is ESKAPE? Initially coined by Dr. Louis Rice, ESKAPE is a handy acronym for…
A few weeks ago, we attended the first annual Commercializing Biotech Innovation Conference in Syracuse, New York. The conference was held in the very new Central New York Biotech Accelerator in Syracuse (which is…
Last month, the FDA announced their approval of Amjevita, a biosimilar to AbbVie's Humira. Humira posted global sales exceeding $14 billion in 2015, and its patents are set to expire in…
Our recent trip to Stockholm and the Nordic Life Science Days conference was quite enlightening, especially as we publicly discuss drug prices (yet again). One presentation at NLSD by SwedenBio enlightened us on how…
In our last post, we presented a model which helps us aggregate a series of variables which, in turn, help us understand why certain therapeutic areas or indications are of greater interest from a licensing perspective than others.
Our aim with this model is to help companies with licenseable assets to frame their “stories” in a way which is compatible with how potential partners approach evaluation and decision-making.
Our first attempt at applying this model is for the HIV/AIDS market. During the 1990s, stories about AIDS were a daily occurrence on the nightly news. Images of celebrities fighting and dying from AIDS seemed to be everywhere. Rock Hudson, Freddy Mercury, Anthony Perkins…the list of celebrities who succumbed to complications from this disease seemed endless.
But what about today? Are there Unmet Needs which can be satisfied via novel therapeutics? And, if so, are they being funded and developed? Are there multinational companies with a stated interested in licensing these innovations once they are sufficiently mature?
In this post, we take a look at these questions.